News | SPECT Imaging | November 08, 2019

New X-ray Technology Could Revolutionize How Doctors Identify Abnormalities

Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

November 8, 2019 — Using ground-breaking technology, researchers at the University of Maryland, Baltimore County (UMBC) and University of Baltimore (UMB) are testing a new method of X-ray imaging that uses color to identify microfractures in bones. Microfractures were previously impossible to see using standard X-ray imaging. The findings associated with this advancement in color (spectral) CT (computed tomography) imaging are published in Advanced Functional Materials.

Since the discovery of X-rays in 1895, the basics of the technology have remained consistent. Doctors and scientists use them to see dense materials, like bones, but the technology's capabilities have been limited. Dipanjan Pan, Ph.D., professor of chemical, biochemical and environmental engineering UMBC, and professor of radiology at UMB, is the corresponding author of this new study. Looking ahead to the next generation of X-ray technology, he asked, "How can we detect a bone microcrack, something that is not visible using X-ray imaging?"

Pan explains that to examine this question, his lab developed nanoparticles that navigate and attach specifically to areas where microcracks exist. He likes to call them "GPS particles." They started conducting this research at the University of Illinois Urbana-Champaign. The researchers have programmed the particles to latch onto the correct area of the microcrack. Once the particles attach to microcracks, they remain there, which is crucial to the imaging process.

The particles contain the element hafnium. A new X-ray-based technique developed by a New Zealand-based company MARS then take CT images of the body and the hafnium particles appear in color. This provides a very clear image of where the bone microcracks are located.

Hafnium is used because its composition makes it detectable to X-rays, generating a signal that can then be used to image the cracks. Pan's lab showed that hafnium is stable enough to be used in testing involving living creatures, and can be excreted safely from the body. The lab has not yet begun testing on humans, but the technology to do so may be available as soon as 2020.

As for other applications for spectral CT imaging with this hafnium breakthrough, the research suggests that this methodology could be used to detect much more serious problems. For example, in order to determine whether a person has a blockage in their heart, doctors often will perform a stress test to detect abnormalities, which comes with a significant amount of risk. One day in the near future, doctors may be able to use spectral CT to determine whether there is a blockage in organs.

"Regular CT does not have a soft-tissue contrast. It cannot tell you where your blood vessels are. Spectral CT can help solve that problem," Pan explained. He notes that although more research is needed to begin using spectral CT in this way, he anticipates that it will be a "tremendous" new tool for radiologists. Fatemeh Ostadhossein, Ph.D., a recent graduate of the Pan lab, was first author on this study.

Related Content

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

News | Coronavirus (COVID-19) | July 09, 2020
July 9, 2020 — With increased lung CT exam paradigms being used in the current...
 Many patients with severe coronavirus disease 2019 (COVID-19) remain unresponsive after surviving critical illness. Investigators led by a team at Massachusetts General Hospital (MGH) now describe a patient with severe COVID-19 who, despite prolonged unresponsiveness and structural brain abnormalities, demonstrated functionally intact brain connections and weeks later he recovered the ability to follow commands

Getty Images

News | Coronavirus (COVID-19) | July 08, 2020
July 8, 2020 — Many patients with severe coronavirus disease 2019 (...
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

News | Coronavirus (COVID-19) | June 26, 2020
June 26, 2020 — In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association wit
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | June 23, 2020
June 23, 2020 — An innovativ...